Last reviewed 2026-04-23 · How we verify

SB27

SB27 is a biosimilar to adalimumab, a TNF-alpha inhibitor.

SB27 is a biosimilar to adalimumab, a TNF-alpha inhibitor. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.

At a glance

Mechanism of action

TNF-alpha inhibitors are a class of biologic medications that block the action of tumor necrosis factor-alpha, a substance in the body that causes inflammation and is involved in autoimmune diseases. By blocking TNF-alpha, SB27 reduces inflammation and slows disease progression in conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Approved indications

• Rheumatoid arthritis
• Psoriatic arthritis
• Ankylosing spondylitis

Common side effects

• Injection site reaction
• Headache
• Fatigue
• Musculoskeletal pain
• Nausea
• Diarrhea
• Abdominal pain
• Dizziness
• Insomnia
• Depression

Key clinical trials

• Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy (PHASE1)
• Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial (PHASE2)
• BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (PHASE2)
• Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (PHASE2)
• Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma (PHASE1, PHASE2)
• A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma (PHASE2)
• Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
• Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.